Priavoid GmbH

Founded on the September 18th, 2017 and headquartered near Düsseldorf, Germany, Priavoid GmbH is a pharmaceutical company focused on the development of innovative disease-modifying therapies for patients with severe neurological disorders.

Priavoid's pharmaceutical development programs are exclusively based on D-enantiomeric peptides (all-D-peptides). The most advanced drug in our pipeline is named PRI-002. The orally available clinical stage drug candidate directly eliminates toxic amyloid-beta (Aß) oligomers for the causal treatment of Alzheimer's disease (AD). Oral administration resulted in significantly improved cognitive read out in three different in vivo models.

The First-in-Human phase I single ascending dose (SAD) and the multiple ascending dose (MAD) clinical trials with PRI-002 were successfully completed, demonstrating excellent safety, tolerability and pharmacokinetic profiles. The MAD part included administration of PRI-002 up to 320 mg/subject/day orally for 28 days to healthy volunteers.

The orally available drug candidate PRI-003 has accomplished successful PoC in an in vivo disease model of Amyotrophic lateral sclerosis (ALS). Priavoid accelerates this research program towards clinical development.

Priavoid's development pipeline is targeting additional orphan and non-orphan CNS disorders caused by misfolded peptides, incl. tauopathies and Parkinson's disease (PD).